BeOne Medicines Ltd
688235
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne’s revenue.
Contact
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
11,000
Stocks News & Analysis
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
stocks
A 5-Star US stock to buy with a near-5% yield
Undervalued by 23%, this cheap dividend stock is a top pick in its sector.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.60 | 9.20 | 0.10% |
| CAC 40 | 7,880.87 | 10.19 | 0.13% |
| DAX 40 | 23,745.06 | 5.59 | 0.02% |
| Dow JONES (US) | 46,316.07 | 68.78 | 0.15% |
| FTSE 100 | 9,299.84 | 15.01 | 0.16% |
| HKSE | 26,622.88 | 494.68 | 1.89% |
| NASDAQ | 22,591.15 | 107.09 | 0.48% |
| Nikkei 225 | 44,910.57 | 133.18 | -0.30% |
| NZX 50 Index | 13,157.68 | 25.12 | 0.19% |
| S&P 500 | 6,661.21 | 17.51 | 0.26% |
| S&P/ASX 200 | 8,880.40 | 11.10 | 0.13% |
| SSE Composite Index | 3,862.53 | 34.43 | 0.90% |